TUSTIN, CA--(Marketwire - August 17, 2010) - Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today it has filed a ‘Notification of Late Filing’ under Rule 12b-25 of the Securities Exchange Act of 1934, as amended with the Securities and Exchange Commission (“SEC”) for its quarterly report on Form 10-Q for the second quarter ended June 30, 2010.
This filing provides an extension for the filing of RPC’s quarterly report on Form 10-Q until August 23, 2009. RPC’s quarterly report on Form 10-Q for the six months ended June 30, 2010 could not be filed within the prescribed period because RPC was unable to compile certain information required to file a timely and accurate report on the Company’s financial condition for the period. This inability could not have been avoided by RPC without unreasonable effort and expense. RPC expects to file its second quarter report within the allotted time. For additional information contact Radient Pharmaceutical Corporation’s Investor Relations at 206.310.5323.
About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its Onko-Sure® In Vitro Diagnostic cancer test. The company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve patient outcomes. Radient Pharmaceutical’s current Onko-Sure® cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com.
Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.
Radient Pharma Contact:
Kristine Szarkowitz
Director-Investor Relations
Email Contact
Tel: 206.310.5323
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati: 
